Clinical trials
Open Label clinical trials
Below are recruiting open label clinical trials, each written for real people, not researchers. We’re tracking 366 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06169579Enrolling by invitationPhase 1
Trial of ND-003 for advanced solid cancers
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
Xiamen, FujianAges 18 years+ - NCT06121297RecruitingPhase 1/Phase 2
CABA-201 treatment for systemic lupus erythematosus
This study tests a new treatment called CABA-201 for people with active systemic lupus erythematosus (SLE). The treatment aims to reduce disease activity and may help those who haven't responded well to other treatments.
Orange, CaliforniaAges 12–65 - NCT06129240Recruiting
Study of a new inhaled treprostinil powder for PH-ILD
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Phoenix, ArizonaAges 18–80 - NCT06105554RecruitingPhase 1/Phase 2
Study of belumosudil for relapsed or refractory multiple myeloma
This trial tests a new drug called belumosudil, alone or with dexamethasone, for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The goal is to see if it can help when other therapies have stopped working.
Houston, TexasAges 18 years+ - NCT06126744RecruitingPhase 1
Study of a virus therapy for recurrent brain cancer
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
New York, New YorkAges 18 years+ - NCT06085716RecruitingPhase 2/Phase 3
Combination therapy for advanced cancer fatigue
This study tests a combination of treatments (including education and counseling) to see if they can reduce severe fatigue in people with advanced cancer. It's for patients who are seen at MD Anderson Cancer Center in Texas and can attend sessions in person or online.
Houston, TexasAges 18 years+ - NCT06085950Recruiting
Ultrasound brain stimulation for hard-to-treat depression
This trial tests whether a gentle ultrasound treatment aimed at the brain can help people with severe depression that hasn't improved with at least two prior medications. It's a first small study to see if the approach is safe and promising.
ParisAges 18–75 - NCT06066580Enrolling by invitationPhase 2
Long-term safety study of sevasemten for Becker muscular dystrophy
This study continues treatment with the investigational drug sevasemten for people with Becker muscular dystrophy who have already been in a previous sevasemten study. The goal is to learn more about the drug's safety and how well it works over a longer period.
Little Rock, ArkansasAges Any age - NCT05985954RecruitingPhase 1
Ulixertinib with cetuximab for colorectal cancer
This trial tests whether the drug ulixertinib, combined with cetuximab (and sometimes encorafenib), can help people with advanced or metastatic colorectal cancer who have already tried EGFR or BRAF-targeted therapy. It aims to find new treatment options for these patients.
Houston, TexasAges 18 years+ - NCT05953584RecruitingPhase 2
Etavopivat for preventing stroke risk in sickle cell children
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
Raipur, ChhattisgarhAges 12–16 - NCT05939414RecruitingPhase 3
Study of radioactive drug for prostate cancer that has spread a little
This study tests a radioactive drug (177Lu-PSMA-617) compared to no immediate treatment in men with prostate cancer that has returned and spread to a few spots (oligometastatic). It aims to see if this treatment delays the spread of cancer and improves outcomes.
Fayetteville, ArkansasAges 18–100 - NCT05389098Recruiting
Finger foods program to help eating in frail seniors
This study tests whether offering easy “finger foods” can improve eating and independence in older adults living in assisted care. It is looking especially at people who are losing weight, have low muscle strength, and may struggle to chew or swallow.
Château-RenaultAges 75–120 - NCT05907057RecruitingPhase 3
Ivosidenib plus azacitidine for newly diagnosed AML
This trial studies ivosidenib together with azacitidine in people newly diagnosed with AML that has an IDH1 R132 gene mutation. It’s meant for patients who are not able to safely receive the strongest (intensive) chemotherapy, with the goal of improving control of the leukemia.
ViennaAges 18 years+ - NCT05884255RecruitingPhase 3
Lutetium brain-sparing therapy for advanced gut and pancreas tumors
This Phase 3 trial tests lutetium (Lu-177) oxodotreotide, a targeted treatment, for people with advanced gut and pancreas neuroendocrine tumors that are low or medium grade (G1 or G2). The study will see whether it helps control the cancer and symptoms in the right patients.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05883748Enrolling by invitationPhase 2/Phase 3
Long-term study of bitopertin for EPP safety and benefit
This trial studies how safe and well bitopertin works over the long term for people with EPP. It mainly includes people who already finished an earlier bitopertin study, to keep tracking side effects and overall progress.
Birmingham, AlabamaAges 12 years+ - NCT05847179RecruitingPhase 2
Treating bone weakness in Werner syndrome
This study tests an investigational drug for people with Werner syndrome who have weak bones (osteopenia or osteoporosis). The goal is to see if the drug is safe and can help improve bone health.
Ann Arbor, MichiganAges 18 years+ - NCT05836259RecruitingPhase 1/Phase 2
TN-201 for heart symptoms from MYBPC3 heart disease
This early trial tests TN-201 to see how safe it is and how well it works to reduce symptoms in adults with MYBPC3-related hypertrophic cardiomyopathy. It’s designed to learn safe dosing, and you may be eligible if you have specific genetic heart changes and ongoing symptoms.
La Jolla, CaliforniaAges 18–75 - NCT05789056RecruitingPhase 2/Phase 3
Study lotion for Netherton syndrome safety and symptom improvement
This trial tests a prescription lotion (QRX003) to see if it is safe and helpful for people with Netherton syndrome. Because the study checks skin symptoms on certain body areas and closely controls other treatments, it may be best for patients who can keep their current regimen stable.
San Diego, CaliforniaAges 14 years+ - NCT05757141RecruitingPhase 1/Phase 2
Study of fosigotifator for vanishing white matter disease
This study tests a new medicine called fosigotifator for people with vanishing white matter disease (VWM), a rare genetic condition that affects the brain and movement. It aims to see if the medicine is safe and helpful for patients from infancy to adulthood.
Boston, MassachusettsAges 6 months+ - NCT05747729RecruitingPhase 1/Phase 2
Study of surufatinib, serplulimab, chemo for neuroendocrine carcinoma
This trial tests a combination of two targeted therapies (surufatinib and serplulimab) plus standard chemotherapy (platinum and etoposide) for people with a rare, aggressive type of cancer called neuroendocrine carcinoma that started outside the lung. The goal is to see if this new combination works better than chemotherapy alone.
Wuhan, HubeiAges 18 years+ - NCT05718817Enrolling by invitationPhase 3
Long-term study of XEN1101 for people with epilepsy
This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.
Phoenix, ArizonaAges 12 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+ - NCT05648591RecruitingPhase 4
Iloperidone study for teens with schizophrenia or bipolar I
This Phase 4 study checks how safe and well-tolerated iloperidone is when used in a typical, open-label way for teenagers. It may help doctors better understand side effects and safety in teens with schizophrenia or bipolar I disorder.
Dothan, AlabamaAges 12–17 - NCT05660642RecruitingPhase 2
Safety and tolerability study for BPL-003 in hard-to-treat depression
This Phase 2 study tests BPL-003 in people with treatment-resistant depression to learn about its safety and how it affects the body and brain. Because it is open-label, everyone knows they are getting the study treatment, and you’ll also need to stop your current antidepressant during the study.
LiverpoolAges 18–75
Hear when a new Open Label trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for open label?
- Yes. Clin2 currently lists 366 recruiting open label studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a open label trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a open label trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.